На этой странице перечислены больницы направления «Хирургическая онкология» (включая Vaginal Cancer Treatment) в Мумбаи, Индия, включая Nanavati Super Specialty Hospital, Kokilaben Dhirubhai Ambani Hospital, Tata Memorial Hospital, Apollo Hospitals, Navi Mumbai и другие.
Спросите нас о «Vaginal Cancer Treatment» в Мумбаи, Индия
Оставьте свои данные — наша команда координации свяжется с вами и расскажет о следующих шагах.
Сравните 17 аккредитованных больниц (Хирургическая онкология) в Мумбаи, Индия
Рекомендуем🇮🇳 Nanavati Super Specialty Hospital
Больница занимает 1-е место в этом списке по указанному рейтингу (5/5, 12 отзывов).
🇮🇳 Kokilaben Dhirubhai Ambani Hospital
Больница занимает 2-е место в этом списке по указанному рейтингу (4.8/5, 1800 отзывов).
🇮🇳 Tata Memorial Hospital
Больница занимает 3-е место в этом списке по указанному рейтингу (4.8/5, 2500 отзывов).
🇮🇳 Apollo Hospitals, Navi Mumbai
Больница занимает 4-е место в этом списке по указанному рейтингу (4.8/5, 512 отзывов).
🇮🇳 Gleneagles Hospital, Mumbai
Больница занимает 5-е место в этом списке по указанному рейтингу (4.8/5, 615 отзывов).
🇮🇳 Lilavati Hospital And Research Centre
Больница занимает 6-е место в этом списке по указанному рейтингу (4.8/5, 724 отзывов).
🇮🇳 Jaslok Hospital
Больница занимает 7-е место в этом списке по указанному рейтингу (4.6/5, 129 отзывов).
🇮🇳 Gleneagles Global Hospitals (Global Hospitals)
Больница занимает 8-е место в этом списке по указанному рейтингу (4.6/5, 183 отзывов).
🇮🇳 Medicover Hospital, Navi Mumbai
Больница занимает 9-е место в этом списке по указанному рейтингу (4.6/5, 143 отзывов).
🇮🇳 KIMS Hospitals, Thane
Больница занимает 10-е место в этом списке по указанному рейтингу (4.6/5, 58 отзывов).
🇮🇳 Fortis Hospital, Mulund
Больница занимает 11-е место в этом списке по указанному рейтингу (4.5/5, 79 отзывов).
🇮🇳 Fortis Hiranandani Hospital, Vashi
Больница занимает 12-е место в этом списке по указанному рейтингу (4.5/5, 83 отзывов).
🇮🇳 Wockhardt Hospital
Больница занимает 13-е место в этом списке по указанному рейтингу (4.4/5, 30 отзывов).
🇮🇳 Wockhardt Super Speciality Hospital
Больница занимает 14-е место в этом списке по указанному рейтингу (4.4/5, 48 отзывов).
🇮🇳 S. L. Raheja Hospital
Больница занимает 15-е место в этом списке по указанному рейтингу (4.4/5, 121 отзывов).
🇮🇳 Saifee Hospital
Больница занимает 16-е место в этом списке по указанному рейтингу (4.3/5, 97 отзывов).
🇮🇳 Dr. L H Hiranandani Hospital
Больница занимает 17-е место в этом списке по указанному рейтингу (4.3/5, 141 отзывов).
Как мы выбираем эти больницы
Больница появляется на этой странице, если направление «Хирургическая онкология» указано среди её специализаций и она находится в Мумбаи, Индия. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».
Как выбрать лучшую больницу для «vaginal cancer treatment» в Мумбаи, Индия?
Выбор подходящей больницы для «vaginal cancer treatment» — важное решение в вашем пути лечения. Вот на что стоит обратить внимание:
Международная аккредитация
Ищите больницу с международной аккредитацией, например JCI или NABH — см. отметки аккредитации у каждой больницы ниже.
Специализация
Убедитесь, что в больнице есть отделение, специализирующееся на «Хирургическая онкология», а не только общая помощь.
Мощность и опыт
Количество коек и год основания, указанные ниже, отражают масштаб и операционный опыт больницы.
Прозрачность стоимости
Запросите детализированную смету перед поездкой — используйте наш калькулятор стоимости для первичной оценки.
Что нужно знать о процедуре «Vaginal Cancer Treatment»
Vaginal cancer is a rare but treatable gynecologic malignancy managed through a multidisciplinary combination of surgery, radiation therapy, and systemic chemotherapy, with five-year survival rates ranging from 84% for Stage I disease to approximately 57% overall across all stages when treated at high-volume oncology centers. GAF Healthcare connects international patients with JCI- and NABH-accredited cancer institutes in India and JCI- and DHA-accredited oncology centers in Dubai and Abu Dhabi, where specialist gynecologic oncologists, radiation physicists, and medical oncologists deliver evidence-based, personalized care at a fraction of Western costs. Patients choose India or the UAE through GAF Healthcare for access to robotic-assisted surgery, intensity-modulated radiation therapy (IMRT), brachytherapy, and targeted immunotherapy protocols aligned with NCCN and ESGO guidelines, combined with end-to-end logistical support from visa facilitation to post-treatment follow-up. Hospital Stay: 7–14 days (varies by stage and treatment modality; surgery alone typically 7–10 days, concurrent chemoradiation may require outpatient attendance over 5–7 weeks) • Total Stay in Country (Fit-to-Fly): 6–10 weeks (patients completing primary surgery are generally fit to fly in 4–6 weeks post-operatively; those completing concurrent chemoradiation require 2–4 weeks of recovery after the final fraction before long-haul travel is safe) • Success Rate: Stage I: ~84% five-year survival; Stage II: ~75%; All-stage combined: ~57% (SEER data, high-volume center outcomes)
Clinical Overview
Vaginal cancer accounts for approximately 1–2% of all gynecologic malignancies, with squamous cell carcinoma (SCC) comprising 85–90% of cases and adenocarcinoma, melanoma, and sarcoma constituting the remainder. The vaginal epithelium is anatomically contiguous with the cervix superiorly and the vulva inferiorly, meaning malignant transformation — most frequently driven by persistent high-risk human papillomavirus (HPV) infection, particularly genotypes 16 and 18 — can produce lesions across a spectrum from vaginal intraepithelial neoplasia (VAIN) to invasive carcinoma. Because the vagina lies in close proximity to the bladder, urethra, rectum, and pelvic sidewall vasculature, even localized disease carries significant implications for organ function, urinary and bowel continence, and sexual health. Staging follows the FIGO 2021 classification system, which substratifies tumors by depth of stromal invasion, parametrial extension, involvement of adjacent organs (bladder, rectum), and lymph node status (pelvic, inguinofemoral, and para-aortic nodes). Stage I disease is confined to the vaginal wall; Stage II extends to paravaginal tissues without reaching the pelvic sidewall; Stage III involves the pelvic sidewall, lower third of the vagina, or regional lymph nodes; and Stage IV denotes invasion of adjacent organs or distant metastasis. Accurate staging requires cross-sectional imaging (MRI pelvis with contrast and PET-CT for metabolic nodal assessment), examination under anesthesia (EUA), and — where VAIN is suspected — colposcopy-directed biopsy. The international standard of care for invasive vaginal cancer is determined primarily by tumor stage, location (upper vs. lower third of vagina), HPV status, patient performance status (ECOG 0–2), and prior pelvic irradiation history. For early-stage upper vaginal lesions in surgical candidates, radical vaginectomy with or without pelvic lymph node dissection (open or robotic-assisted) is preferred. For the majority of patients — particularly those with Stage II–IV disease or lower-vaginal tumors abutting the urethra — concurrent cisplatin-based chemoradiation using external beam radiotherapy (EBRT) via IMRT or volumetric modulated arc therapy (VMAT) combined with intracavitary or interstitial brachytherapy is the definitive treatment approach, consistent with NCCN Category 2A recommendations. Systemic chemotherapy protocols (carboplatin/paclitaxel or pembrolizumab for PD-L1-positive or MSI-H tumors) are used in the metastatic or recurrent setting.
Who is a Candidate?
• Confirmed histopathologic diagnosis of vaginal carcinoma (SCC, adenocarcinoma, or other histology) on colposcopy-directed biopsy or EUA biopsy • FIGO Stage I–IVA disease being considered for curative-intent treatment; Stage IVB patients evaluated for palliative or systemic protocols • ECOG Performance Status 0–2 (sufficient functional reserve for surgery or chemoradiation) • Adequate bone marrow reserve: ANC ≥1,500/µL, platelets ≥100,000/µL, hemoglobin ≥9 g/dL (for cisplatin eligibility) • Adequate renal function: GFR ≥50 mL/min (creatinine clearance assessed before platinum-based chemotherapy) • No prior pelvic irradiation exceeding tolerance doses (prior RT history requires brachytherapy dose optimization and is a relative contraindication to further EBRT) • HPV genotyping and PD-L1 expression / MSI/MMR status testing for systemic therapy eligibility (pembrolizumab in PD-L1 CPS ≥10 or MSI-H/dMMR tumors) • Required pre-treatment diagnostics: MRI pelvis with contrast (tumor volumetry and parametrial assessment), PET-CT whole body (nodal and distant metastasis staging), colposcopy ± cervical biopsy (to exclude primary cervical cancer), cystoscopy and proctoscopy (if Stage III–IVA), CBC, CMP, LFTs, CA-125, SCC antigen, HIV serology, HPV genotype panel • Contraindications to surgery: prior extensive pelvic surgery with hostile pelvis, unresectable parametrial disease, significant cardiopulmonary comorbidity precluding general anesthesia (ASA Class IV), patient refusal of surgical intervention • Contraindications to concurrent cisplatin: GFR <50 mL/min, pre-existing grade ≥2 peripheral neuropathy, cisplatin allergy (carboplatin substitution protocol available) • Relative contraindications to brachytherapy: prior pelvic irradiation at/near tolerance, active pelvic infection, severe vaginal stenosis precluding applicator placement
Treatment Options & Approaches
SURGICAL APPROACHES Radical Vaginectomy: Indicated for Stage I upper-vaginal SCC in patients without prior irradiation. En-bloc resection of the vagina with adequate margins (≥1 cm), often combined with pelvic lymph node dissection (sentinel node biopsy increasingly utilized). Vaginal reconstruction using split-thickness skin grafts, Singapore (pudendal thigh) flaps, or gracilis myocutaneous flaps is performed concurrently by reconstructive surgeons to preserve sexual function. Robotic-Assisted Radical Vaginectomy + Pelvic Lymphadenectomy (da Vinci Xi Platform): Available at select high-volume centers in India (Tata Memorial, Apollo, Manipal) and UAE (Cleveland Clinic Abu Dhabi, Mediclinic City). Offers 10× magnified 3D visualization, wristed instrumentation enabling precise dissection in the narrow bony pelvis, reduced blood loss (mean 150–200 mL vs. 400–600 mL open), shorter hospitalization, and faster return to ambulation. Particularly advantageous for upper-vaginal tumors near the bladder trigone. Pelvic Exenteration: Reserved for recurrent or persistent central disease after prior chemoradiation. Anterior exenteration (bladder + vagina), posterior exenteration (rectum + vagina), or total pelvic exenteration depending on organ involvement. Requires ileal conduit or neobladder reconstruction and colostomy where applicable. Performed by multidisciplinary surgical teams. CONCURRENT CHEMORADIATION (DEFINITIVE — FIRST-LINE FOR MOST PATIENTS) External Beam Radiotherapy (EBRT): Delivered using IMRT or VMAT to the primary tumor, whole pelvis, and involved lymph node regions. Total dose: 45–50.4 Gy in 25–28 fractions over 5–6 weeks. IMRT significantly reduces dose to bladder, rectum, and bowel compared to conventional 4-field box technique, lowering rates of radiation cystitis, proctitis, and small bowel toxicity. Daily image-guided RT (IGRT) with cone-beam CT (CBCT) ensures millimetric accuracy for pelvic organ motion. Brachytherapy (Internal Radiation): Administered after EBRT completion as a high-dose-rate (HDR) boost to the primary tumor volume. Intracavitary brachytherapy using vaginal cylinder or ring applicators is used for superficial lesions; interstitial brachytherapy (template-guided perineal implantation with titanium needles using the Martinez Universal Perineal Interstitial Template — MUPIT) is required for bulky or deeply invasive tumors. MRI-guided adaptive brachytherapy (MR-IGBT), following the GEC-ESTRO recommendations, allows personalized dose escalation to the high-risk CTV while constraining doses to the rectum (D2cc <65–70 Gy EQD2) and bladder (D2cc <85–90 Gy EQD2). This approach is available at advanced brachytherapy centers in both India and UAE. Concurrent Chemotherapy: Weekly cisplatin 40 mg/m² IV (standard radiosensitizer) administered during EBRT, typically 5–6 cycles. Carboplatin AUC 2 weekly substituted for cisplatin in patients with renal impairment or neuropathy. SYSTEMIC THERAPY (RECURRENT / METASTATIC DISEASE) Platinum-Based Chemotherapy: Carboplatin AUC 5 + paclitaxel 175 mg/m² every 3 weeks is the preferred first-line doublet for metastatic SCC. Immunotherapy: Pembrolizumab (anti-PD-1) is approved (FDA Breakthrough, ESMO guideline-supported) for PD-L1-positive (CPS ≥10) or MSI-H/dMMR recurrent/metastatic vaginal cancer based on KEYNOTE-158 data, with an objective response rate of approximately 14–17% and durable responses in biomarker-selected patients. Combination pembrolizumab + chemotherapy is under active investigation. Targeted Therapy: Bevacizumab (anti-VEGF) may be added to platinum-doublet chemotherapy in recurrent disease by analogy with cervical cancer data (GOG 240 extrapolation), though vaginal-specific randomized data remain limited. Tumor molecular profiling (Foundation One CDx or local NGS panels) is recommended to identify actionable alterations (PIK3CA, KRAS, ERBB2 amplification) for clinical trial eligibility. FERTILITY PRESERVATION: In carefully selected young patients with Stage I upper-vaginal tumors, fertility-sparing approaches (wide local excision with close follow-up, or radical trachelectomy if the cervix is involved) may be discussed at specialized centers. Ovarian transposition (oophoropexy) prior to pelvic irradiation preserves ovarian function in pre-menopausal women.
Восстановление
STEP 1 — PRE-ARRIVAL CONSULTATION (Weeks 1–2 before travel) Patients submit existing biopsy reports, imaging (MRI/PET-CT), operative notes, and pathology to GAF Healthcare's oncology coordination team. A virtual multidisciplinary tumor board (gynecologic oncologist, radiation oncologist, medical oncologist, radiologist) reviews the case and provides a written treatment recommendation and itemized cost estimate within 48–72 hours. Visa documentation (e-Medical Visa for India; UAE entry visa support) is initiated simultaneously. STEP 2 — ARRIVAL AND STAGING WORKUP (Days 1–5 in country) Upon arrival, GAF Healthcare's ground team facilitates airport pickup and hotel/hospital guest house check-in. The patient undergoes repeat or supplementary staging: MRI pelvis with gadolinium contrast, PET-CT if not recently performed (within 4 weeks), examination under anesthesia (EUA) with colposcopy, cystoscopy (Stage ≥III), CBC, CMP, GFR, SCC antigen, CA-125, and biomarker profiling (HPV genotype, PD-L1 CPS, MSI/MMR). An anesthesiology pre-assessment is completed for surgical candidates. STEP 3 — MULTIDISCIPLINARY TUMOR BOARD CONFIRMATION (Day 5–7) All staging data are presented at the institutional tumor board. Final treatment pathway is confirmed (surgery vs. definitive chemoradiation vs. combined approach), and consent is obtained. Radiation planning CT simulation with vaginal fiducial marker insertion is performed for chemoradiation candidates; surgical scheduling is confirmed for operative candidates. STEP 4A — SURGERY (Day 7–10, if surgical candidate) Robotic-assisted or open radical vaginectomy ± pelvic lymphadenectomy is performed under general anesthesia. Operative time: 2.5–5 hours. ICU observation for 12–24 hours post-operatively. Foley catheter remains in situ for 7–14 days (nerve-sparing technique reduces duration). Pathologic assessment of margins and lymph nodes determines need for adjuvant radiotherapy. Hospital stay: 7–10 days. Drain removal and wound check prior to discharge. STEP 4B — CONCURRENT CHEMORADIATION (Weeks 1–7, if non-surgical / definitive CRT candidate) EBRT via IMRT/VMAT begins: 25–28 daily fractions (Monday–Friday) over 5–6 weeks. Weekly cisplatin infusion (Day 1, 8, 15, 22, 29, 36) administered in the day-care chemotherapy unit with standard antiemetic prophylaxis (ondansetron + dexamethasone + fosaprepitant). Patients are managed on an outpatient or short-stay basis and monitored weekly for hematologic toxicity (CBC), renal function, and radiation-related mucositis. STEP 5 — BRACHYTHERAPY BOOST (Weeks 7–9) Following EBRT completion, HDR brachytherapy boost is delivered in 2–5 fractions over 1–2 weeks under sedation or spinal anesthesia. Interstitial template placement (MUPIT) for bulky tumors is performed as a minor surgical procedure with 1–2 night admission. MRI between fractions (adaptive brachytherapy) allows dose optimization. STEP 6 — RECOVERY AND PRE-DISCHARGE ASSESSMENT (Days 60–70 for CRT; Day 28–42 for surgery) Post-treatment PET-CT or MRI is scheduled 8–12 weeks after completion of definitive therapy to assess treatment response (RECIST 1.1 / PERCIST criteria). Acute toxicity management: vaginal dilator therapy initiated 2–4 weeks after brachytherapy completion to prevent stenosis; pelvic floor physiotherapy; topical estrogen for vaginal mucosal recovery (if not contraindicated). Nutritional and lymphedema assessments completed. STEP 7 — FIT-TO-FLY CLEARANCE AND DEPARTURE (Weeks 6–10) Surgical patients: cleared for long-haul flight at 4–6 weeks post-operatively if wound healing is complete, no DVT risk factors unmanaged, and no post-surgical complications. CRT patients: cleared at 2–4 weeks after the final brachytherapy fraction, provided acute bowel and bladder toxicity has stabilized to Grade ≤1 (CTCAE v5.0). GAF Healthcare issues a discharge summary, pathology report, treatment summary, and referral letter for the patient's home oncologist. Thromboprophylaxis guidance (low-molecular-weight heparin for flights >6 hours) is provided. STEP 8 — REMOTE FOLLOW-UP GAF Healthcare coordinates quarterly telemedicine follow-up with the treating gynecologic oncologist for the first 2 years, then semi-annually. Surveillance includes clinical examination, vault smear/cytology, and pelvic MRI every 6 months for 2 years.
Возможные риски
Vaginal cancer treatment carries meaningful procedural and treatment-related risks that patients must understand before committing to a care pathway. Surgical risks include intraoperative hemorrhage (estimated blood loss >500 mL in up to 12% of radical vaginectomies), ureterovaginal or vesicovaginal fistula formation (2–5% in non-irradiated fields; higher post-radiation), wound dehiscence, pelvic lymphocele requiring drainage, deep vein thrombosis and pulmonary embolism (prophylaxed with LMWH and compression devices), and genitourinary dysfunction including urinary incontinence or retention requiring intermittent self-catheterization. Sexual dysfunction — including vaginal shortening, dyspareunia, and anorgasmia — affects a substantial proportion of patients and requires dedicated pelvic floor rehabilitation and psychosexual counseling. Radiation-related toxicities include acute radiation proctitis (rectal bleeding, tenesmus), radiation cystitis (dysuria, hematuria), small bowel enteritis, and long-term complications of vaginal stenosis (seen in up to 30–58% without dilator use), chronic proctitis, bladder contracture, and rare radiation-induced secondary malignancy. Brachytherapy-specific risks include applicator displacement between fractions, perineal or vaginal perforation during interstitial implantation, and fistula formation (rectovaginal or vesicovaginal) particularly in heavily pre-irradiated patients. Cisplatin chemotherapy risks include nephrotoxicity (prevented by aggressive pre/post-hydration and renal function monitoring), peripheral neuropathy (cumulative dose-dependent), ototoxicity, myelosuppression (nadir Day 10–14), and nausea/vomiting. Immunotherapy with pembrolizumab carries immune-related adverse events (irAEs) including immune-mediated pneumonitis (2–5%), colitis (1–2%), hepatitis, endocrinopathies (hypothyroidism in 8–10%), and rare severe events such as myocarditis (<1%). All patients should receive DVT prophylaxis during long-haul international flights, and GAF Healthcare ensures that fit-to-fly clearance is individualized and documented prior to departure.
Почему GAF Healthcare
GAF Healthcare provides a fully integrated non-medical support framework designed to eliminate logistical burden for international oncology patients and their families. VISA ASSISTANCE — INDIA: GAF Healthcare's dedicated visa team guides patients through the e-Medical Visa (eMV) application process on the Indian government's official portal (indianvisaonline.gov.in). The eMV grants triple-entry with 60-day validity per entry and is typically processed within 3–5 business days. An accompanying attendant (spouse, family member) is eligible for an e-Medical Attendant Visa simultaneously. GAF Healthcare prepares all required supporting documents: hospital invitation letter on institutional letterhead, treating physician credentials, and patient medical summary. VISA ASSISTANCE — UAE (DUBAI / ABU DHABI): Citizens of over 120 countries receive visa-on-arrival or visa-free entry to the UAE for 30–90 days, covering the full treatment duration for most patients. For nationalities requiring prior visa arrangements, GAF Healthcare facilitates the UAE Medical Entry Permit application through the Federal Authority for Identity and Citizenship. Our Dubai coordination team liaises with the treating hospital to obtain the required sponsorship letter from the DHA-licensed facility. AIRPORT TRANSFERS: Private, air-conditioned vehicle transfers are arranged for all arrival and departure logistics, including hospital-to-hotel and inter-facility transfers during the treatment course. Vehicles are wheelchair-accessible where required, and transfer schedules are coordinated with flight arrival/departure times. DEDICATED PATIENT COORDINATORS AND INTERPRETERS: Each patient is assigned a dedicated GAF Healthcare case manager who serves as the single point of contact throughout the treatment journey. Certified medical interpreters are available for Arabic, Russian, Swahili, French, Bengali, and other languages, accompanying patients to all clinical consultations, informed consent discussions, and discharge briefings to ensure full comprehension of treatment plans. ACCOMMODATION FOR ATTENDANTS: GAF Healthcare arranges partner-rate accommodation for the patient's attendant at serviced apartments, hospital guest houses, or curated hotels within a 10–15 minute radius of the treating facility. For patients undergoing 5–7 week chemoradiation courses, long-stay apartment options with kitchenette facilities are secured at negotiated monthly rates. Meal preferences, dietary restrictions (halal, vegetarian, etc.), and accessibility requirements are accommodated. CONTINUITY OF CARE: Upon treatment completion, GAF Healthcare prepares a comprehensive departure pack including the final treatment summary, pathology and imaging reports on encrypted digital media, a written surveillance schedule, and a warm referral letter addressed to the patient's home oncologist. Telemedicine follow-up appointments with the treating specialist are pre-scheduled before the patient departs.
Частые вопросы о процедуре «Vaginal Cancer Treatment»
What is the cost of Vaginal Cancer Treatment in India compared to the UAE?
How long do I need to stay in India or the UAE before I am fit to fly home after Vaginal Cancer Treatment?
What is the success rate for Vaginal Cancer Treatment?
Похожие страницы
Как GAF Healthcare помогает выбрать лучшую больницу для «vaginal cancer treatment» в Мумбаи, Индия
Найдите лучшие больницы для «vaginal cancer treatment» в Мумбаи, Индия
На этой странице представлено 17 больниц в Мумбаи, Индия, чтобы вы могли сравнить аккредитацию и специализации в одном месте.
Поддержка, когда она нужна
Отправьте нам свои медицинские отчёты в WhatsApp или по email — наша медицинская команда изучит их и предложит больницу и план лечения.
Прозрачные, всё включено цены
Мы предоставляем единую детализированную смету, покрывающую расходы больницы и проживание — без скрытых платежей.
Организация визы, поездки и проживания
После выбора больницы мы помогаем оформить визовое приглашение, забронировать проживание рядом с больницей и организовать трансфер.
Хотите узнать примерную стоимость лечения? Используйте наш калькулятор стоимости для персональной оценки.
Частые вопросы о «Vaginal Cancer Treatment» в Мумбаи, Индия
Сколько больниц направления «Хирургическая онкология» представлено в Мумбаи, Индия?
Как вы выбираете больницы для списка?
Сколько стоит лечение в Мумбаи, Индия?
Следующий шаг
Отправьте нам свои медицинские отчёты — наша команда предложит больницу и план лечения для «Vaginal Cancer Treatment» в Мумбаи, Индия.
Свяжитесь с нами, если заметите неточность на этой странице.